BridgeBio Pharma Inc
2CL
Company Profile
Business description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Contact
3160 Porter Drive
Suite 250
Palo AltoCA94304
USAT: +1 650 391-9740
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
730
Stocks News & Analysis
stocks
3 Warren Buffett stocks to avoid today
These are the most overvalued stocks in Berkshire Hathaway’s portfolio.
stocks
Should you invest in small caps?
With small capitalisation stocks gaining momentum, there are important considerations to determine whether they are right for your portfolio.
stocks
Strong second half anticipated for ASX mining play
A more focused business model should benefit the company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,062.30 | 0.80 | 0.01% |
| CAC 40 | 7,795.42 | 32.03 | -0.41% |
| DAX 40 | 23,534.83 | 131.98 | -0.56% |
| Dow JONES (US) | 45,947.32 | 173.96 | -0.38% |
| FTSE 100 | 9,213.98 | 36.45 | -0.39% |
| HKSE | 26,335.27 | 149.41 | -0.56% |
| NASDAQ | 22,384.70 | 113.16 | -0.50% |
| Nikkei 225 | 45,442.50 | 312.43 | -0.68% |
| NZX 50 Index | 13,111.73 | 42.06 | -0.32% |
| S&P 500 | 6,604.72 | 33.25 | -0.50% |
| S&P/ASX 200 | 8,771.60 | 2.90 | -0.03% |
| SSE Composite Index | 3,846.03 | 7.27 | -0.19% |